- Home
- ECPG vs SBFM Comparison
ECPG vs SBFM Comparison
Compare ECPG & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECPG
- SBFM
- Stock Information
- Founded
- ECPG 1998
- SBFM 2006
- Country
- ECPG United States
- SBFM United States
- Employees
- ECPG N/A
- SBFM N/A
- Industry
- ECPG Finance Companies
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- ECPG Finance
- SBFM Health Care
- Exchange
- ECPG Nasdaq
- SBFM Nasdaq
- Market Cap
- ECPG N/A
- SBFM 4.9M
- IPO Year
- ECPG 1999
- SBFM N/A
- Fundamental
- Price
- ECPG $35.15
- SBFM $1.39
- Analyst Decision
- ECPG Strong Buy
- SBFM Strong Buy
- Analyst Count
- ECPG 3
- SBFM 1
- Target Price
- ECPG $62.67
- SBFM $15.00
- AVG Volume (30 Days)
- ECPG 335.7K
- SBFM 4.4M
- Earning Date
- ECPG 05-07-2025
- SBFM 05-19-2025
- Dividend Yield
- ECPG N/A
- SBFM N/A
- EPS Growth
- ECPG N/A
- SBFM N/A
- EPS
- ECPG N/A
- SBFM N/A
- Revenue
- ECPG $1,316,361,000.00
- SBFM $34,874,283.00
- Revenue This Year
- ECPG $21.62
- SBFM $192.48
- Revenue Next Year
- ECPG $10.12
- SBFM N/A
- P/E Ratio
- ECPG N/A
- SBFM N/A
- Revenue Growth
- ECPG 7.66
- SBFM 44.75
- 52 Week Low
- ECPG $26.45
- SBFM $1.17
- 52 Week High
- ECPG $51.77
- SBFM $33.60
- Technical
- Relative Strength Index (RSI)
- ECPG 56.74
- SBFM 38.67
- Support Level
- ECPG $28.93
- SBFM $1.17
- Resistance Level
- ECPG $34.97
- SBFM $1.59
- Average True Range (ATR)
- ECPG 1.75
- SBFM 0.16
- MACD
- ECPG 0.90
- SBFM 0.04
- Stochastic Oscillator
- ECPG 100.00
- SBFM 51.28
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.